Table 1.
Patient characteristics
| Sex | Patients (%) |
|---|---|
| Female | 0 (0.0 %) |
| Male | 45 (100 %) |
| Age, median (year, range) | 65 (60–72) |
| Primary tumor site | |
| Bladder | 30 (66.7 %) |
| Ureter or renal pelvic | 6 (13.3 %) |
| Ureter or renal pelvic with bladder | 9 (20.0 %) |
| Nodal status | |
| N0 | 6 (13.3 %) |
| N1 | 8 (17.8 %) |
| N2 | 19 (42.2 %) |
| N3 | 12 (26.7 %) |
| Distant metastatic site at the time of MVAC administration | |
| Lung | 21 (46.7 %) |
| Bone | 16 (35.6 %) |
| Liver | 9 (20.0 %) |
| Other | 4 (8.9 %) |
| Absence | 16 (35.6 %) |
| Single | 13 (28.9 %) |
| Multiple | 16 (35.6 %) |
| ECOG performance status (PS) | |
| PS 0 | 20 (44.4 %) |
| PS 1 | 23 (51.1 %) |
| PS 2 | 2 (4.4 %) |
MVAC methotrexate vinblastine Adriamycin cisplatin, ECOG Easton Cooperative Oncologic Group